Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus

Journal of Cellular Physiology

Volumn 212, Issue 1, 2007, Pages 148-156

  Citores, Lucía ^a   Bai, Ling ^b,c   Sørensen, Vigdis ^b   Olsnes, Sjur ^b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLUCOSIDASE; STAT1 PROTEIN;

ANIMAL CELL; ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN COS1; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; GOLGI COMPLEX; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION; GOLGI APPARATUS; HUMANS; PHOSPHORYLATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 34249876376     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21014     Document Type: Article

References (50)

1. Adar R, Monsonego-Ornan E, David P, Yayon A. 2001 Differential activation of cystine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17:860-868.
2. Basilico C, Moscatelli D. 1991 The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165.
3. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA. 2000. District missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 67:1411-1421.
4. Bivona TG, Philips MR. 2003. Ras pathway signaling on endomembranes. Curr Opin Cell Biol 15:136-142.
5. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le Bourhis X. 2000. FGF signals for cell proliferation and migration through different pathways, Cytokine Growth Factor Rev 11:295-302.
6. Burgess WH, Maciag T. 1989. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575-606.
7. Charest A, Khelfets V, Park J, Lane K, McMahon K, Nutt CL, Housman D. 2003. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci USA 100:916-921.
8. Citores L, Khnykin D, Sorensen V, Wesche J, Klingenberg O, Wiedlocha A, Olsnes S. 2001. Modulation of intracellular transport of acidic fibroblast growth factor by mutations in the cytoplasmic receptor domain. J Cell Sci 114:1677-1689.
9. Darnell JE, Jr. 1997. STATs and gene regulation. Science 277:1630-1635.
10. Darnell JE, Jr. Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
11. d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. 1998. Constitutive activation of fibroblastgrowth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 9:71-78.
12. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921.
13. Ferri KF, Kroemer G, 2001. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3:E255-E263.
14. Giri D, Ropiquet F, Ittmann M. 1999, Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071.
15. Gospodarowicz D, Neufeld G, Schweigerer L, 1986. Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Differ 19:1-17.
16. Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D, Pebusque MJ. 2003. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8:19)(p12: q13.3). Blood 101:286-288.
17. Habib AA, Chun SJ, Neel BG, Vartanian T. 2003. Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1:219-233.
18. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. 2000. Transformation and Statactivation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19:3309-3320.
19. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314.
20. Hughes SE. 1997. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 45:1005-1019.
21. Ihle JN. 1996. STATs: Signal transducers and activators of transcription. Cell 84:331-334.
22. Jaye M, Schlessinger J, Dionne CA. 1992. Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction. Biochim Biophys Acta 1135:185-199.
23. Johnson DE, Williams LT. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41.
24. Johnson LR, McCormack SA, Yang CH, Pfeffer SR, Pfeffer LM. 1999. EGF induces nuclear translocation of STAT2 without tyrosine phosphorylation in intestinal epithelial cells. Am J Physiol 276:C419-C425.
25. Klingenberg O, Wiedlocha A, Rapak A, Khnykin D, Citores L, Olsnes S. 2000. Requirement for C-terminal end of fibroblast growth factor receptor 4 in translocation of acidic fibroblast growth factor to cytosol and nucleus. J Cell Sci 113:1827-1838.
26. Koziczak M, Hynes NE. 2004. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 279:50004-50011.
27. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventura J. 1998. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 273:13007-13014.
28. Leonard WJ, O'Shea JJ. 1998. Jaks and STATs: Biological implications. Annu Rev Immunol 16:293-322.
29. Li C, Chen L, Iwacz T, Kitagawa M, Fu XY, Deng CX. 1999. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and Ink4 cell cycle inhibitors. Hum Mol Genet 8:35-44.
30. Lievens PM, Liboi E. 2003. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278:17344-17349.
31. Lievens PM, Mutinelli C, Baynes D, Liboi E. 2004. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling, J Biol Chem 279:43254-43260.
32. McBride KM, Banninger G, McDonald C, Reich NC. 2001 Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha. EMBO J 21:1754-1763.
33. Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W, Berger MS. 1994. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 54:2794-2799.
34. Muenke M, Schell U. 1995. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11:308-313.
35. Myoken Y, Myoken Y, Okamoto T, Sato JD, Kan M, McKeehan WL, Nakahara M, Takada K. 1996. Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in human malignant salivary gland tumours. J Pathol 178:429-436.
36. Ollendorff V, Guasch G, Isnardon D, Galindo R, Birnbaum D, Pebusque MJ. 1999. Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem 274:26922-26930.
37. Ornitz DM. 2000. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22:108-112.
38. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2:REVIEWS300S.
39. O'Shea JJ. 1997. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity 7:1-11.
40. Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165-197.
41. Rios RM, Bornens M. 2003. The Golgi apparatus at the cell centre. Curr Opin Cell Biol 15:60-66.
42. Ross TS, Gilliland DG. 1999. Transforming properties of the Huntington interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem 274: 22328-22336.
43. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13:1361-1366.
44. Smedley D, Demiroglu A, Abdul-Rauf M, Heath C, Cooper C, Shipley J, Cross NC. 1999. ANF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia 1:349-355.
45. Sorensen V, Brech A, Khnykin D, Kolpakova E, Citores L, Olsnes S. 2004. Deletion mutant of FGFR4 induces onion-like membrane structures in the nucleus. J Cell Sci 117:1807-1819.
46. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY. 1997. Activation of Stat1 by mutant fibroblast growth factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386:288-292.
47. Webster MK, Donoghue DJ. 1997. FGFR activation in skeletal disorders: Too much of a good thing. Trends Genet 13:178-182.
48. Wiedlocha A, Falnes PO, Madshus IH, Sandvig K, Olsnes S. 1994. Dual mode of signal transduction by externally added addic fibroblast growth factor. Cell 76: 1039-1051.
49. Wiedlocha A, Falnes PO, Rapak A, Munoz R, Klingenberg O, Olsnes S. 1996. Stimulation of proliferation of a human osteosarcoma cell line by exogenous acidic fibroblast growth factor requires both activation of receptor tyrosine kinase and growth factor internalization. Mol Cell Biol 16:270-280.
50. Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK. 1995. Functions of fibroblast growth factors and their receptors. Curr Biol 5:500-507.